BD Launches New Robotic System to Automate Clinical Flow Cytometry

News provided by

Jun 12, 2023, 16:10 ET

BD FACSDuet™ Premium System Leverages Robotics to Automate Sample Preparation for Greater Standardization in Clinical Flow Cytometry Diagnostics

FRANKLIN LAKES, N.J., June 12, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the worldwide commercial launch of a new automated instrument that prepares samples for clinical diagnostics using flow cytometry, enabling a complete "walkaway" workflow solution designed to improve standardization and reproducibility in cellular diagnostics.

By being integrated with the flow cytometer, the BD FACSDuet™ Premium System enables a “walkaway” workflow solution that requires fewer manual steps, fewer resources and less user hands-on time than previous solutions.

The BD FACSDuet™ Premium Sample Preparation System leverages liquid-handling robotics to automate the entire sample preparation process, for both in vitro diagnostics (IVD) and user-defined tests, including cocktailing, washing and centrifuging – and then automatically transfers samples to the physically integrated BD FACSLyric™ Clinical Flow Cytometry System, without human interaction. By being integrated with the flow cytometer, the BD FACSDuet™ Premium System enables a "walkaway" workflow solution that requires fewer manual steps, fewer resources and less user hands-on time than previous solutions.

Flow cytometry is an essential tool for clinical diagnostics, commonly utilized in the diagnosis and management of diseases like cancer.

"Our clinical customers have long trusted BD and our best-in-class products to standardize every step of the clinical lab workflow – from panel creation to sample preparation to analysis to report," said Steve Conly, worldwide president, BD Biosciences. "The flagship BD FACSLyric™ Flow Cytometry System is one of the fastest adopted clinical instruments in the world and now together with the FACSDuet™ Premium System, which has achieved IVD status in the U.S. and Europe, we usher in greater levels of automation so that our customers can focus more of their valuable time on analyzing and interpreting samples and impacting outcomes."

The BD FACSDuet™ Premium System is now available to order through local sales representatives. More information is available at bdbiosciences.com and in the recent BD Biosciences Power of Automation Keynote Presentation.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

Contacts:

Media:	Investors:

Troy Kirkpatrick	Francesca DeMartino
VP, Public Relations	SVP, Head of Investor Relations
858.617.2361	201.847.5743
[email protected]	[email protected]